alytas therapeutics collaborates with spin-off from the German Diabetes Center - Seite 2

 

Contact

Information for journalists: IRF Reputation AG, Valentin Handschin, [e-mail]

Information for investors: Xlife Sciences AG, Dennis Lennartz, [e-mail]

Xlife Sciences AG

 

Talacker 35

8001 Zürich

Telefon: [phone]

E-Mail: [e-mail]

Internet: www.xlifesciences.ch

ISIN: CH0461929603

WKN: A2PK6Z

Börsen: SIX Swiss Exchange  

About Xlife Sciences AG (SIX: XLS)

Xlife Sciences is a Swiss company focused as incubator and accelerator on the value development and commercialization of promising research projects from universities and other research institutions in the life sciences sector, with the aim of providing solutions for high unmet medical needs and a better quality of life. The goal is to bridge research and development to healthcare markets. Xlife Sciences takes carefully selected projects in the four areas of technological platforms, biotechnology/ therapies, medical technology, and artificial intelligence/digital health to the next stage of development, and participates in their subsequent performance. For more information, visit www.xlifesciences.ch

Disclaimer

Some of the information contained in this media release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Xlife Sciences undertakes no obligation to publicly update or revise any forward-looking statements.